Topline results expected in Q3 2025. Praxis Precision Medicines reports positive Phase 2 EMBOLD study results for relutrigine in treating SCN2A and SCN8A developmental and epileptic encephalopathy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback